Back to X-Linked Lymphoproliferative Disease Due to Sh2d1a Deficiency

X-Linked Lymphoproliferative Disease Due to Sh2d1a Deficiency — Clinical Trials

MONDO:00245512 activeLast updated: Mar 21, 2026, 10:57 PM

Trial Landscape

X-Linked Lymphoproliferative Disease Due to Sh2d1a Deficiency has an emerging clinical trial program, driven by drug treatment and biological therapy.

Recruiting

Active Trials

By Approach

Drug Treatment2

Biological Therapy2

By Phase

Phase 1

1 trials are observational or have no phase designation.

Sponsor Types

Academic/Other2

Trial Locations

United States2 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

2 Trials

Phase 1Active, Not Recruiting

NCT01494103

Administration of Donor T Cells With the Caspase-9 Suicide Gene

Sponsor:Baylor College of Medicine

United StatesStarted: Nov 2011Est. completion: May 2029Updated: Jul 2025

Not ApplicableActive, Not Recruiting

NCT01652092

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Sponsor:Masonic Cancer Center, University of Minnesota

United StatesStarted: Sep 2012Est. completion: Dec 2026Updated: Jan 2026

Stay informed about clinical trials for X-Linked Lymphoproliferative Disease Due to Sh2d1a Deficiency.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 21, 2026 at 10:57 PM